← Back to Search

Lipoglycopeptide Antibiotic

Telavancin for Pneumonia (ATTAIN1 Trial)

Phase 3
Waitlist Available
Led By G. Ralph Corey, MD
Research Sponsored by Cumberland Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Clinical signs and symptoms consistent with pneumonia acquired after at least 48 hours of continuous stay in an inpatient acute or chronic care facility or acquired within 7 days after being discharged from a hospitalization of greater than or equal to 3 days duration.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 - 14 days following end of antibiotic treatment
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group
Pivotal Trial

Summary

Study 0015 (NCT00107952) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.

Eligible Conditions
  • Pneumonia

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 - 14 days following end of antibiotic treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 - 14 days following end of antibiotic treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Clinical Response

Side effects data

From 2016 Phase 4 trial • 8 Patients • NCT02392208
13%
New onset atrial flutter
100%
80%
60%
40%
20%
0%
Study treatment Arm
Telavancin Before Hemodialysis
Telavancin After Hemodialysis

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: TelavancinExperimental Treatment1 Intervention
Group II: VancomycinActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Telavancin
FDA approved

Find a Location

Who is running the clinical trial?

Cumberland PharmaceuticalsLead Sponsor
62 Previous Clinical Trials
8,680 Total Patients Enrolled
2 Trials studying Pneumonia
1,834 Patients Enrolled for Pneumonia
G. Ralph Corey, MDPrincipal InvestigatorDuke University
8 Previous Clinical Trials
5,085 Total Patients Enrolled
1 Trials studying Pneumonia
771 Patients Enrolled for Pneumonia
~37 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top